Financial Performance - BioHarvest Sciences Inc. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.15, and an improvement from a loss of $0.35 per share a year ago, indicating an earnings surprise of 13.33% [1] - The company posted revenues of $7.86 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.42%, and showing an increase from $5.34 million in the same quarter last year [2] Stock Performance - BioHarvest Sciences Inc. shares have increased approximately 6.8% since the beginning of the year, outperforming the S&P 500, which gained 0.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $8.77 million, and for the current fiscal year, it is -$0.30 on revenues of $40.4 million [7] - The estimate revisions trend for BioHarvest Sciences Inc. is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which BioHarvest Sciences Inc. belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% of industries [8]
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates